A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Financial Summary
| Share Statistics | OBX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $874.8 | $286.3 | 43% |
|
| Shares Out (Mil) | 0.1 | 54.2 | 1% |
|
| Institutional Ownership | na | 92.8% | na |
|
| Float (Mil) | na | 39.7 | na |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 69 | 534 | 31% |
|
| Price Change (52-week) |
na | 58.7% | na |
|
| Growth | OBX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | OBX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($95) | ($43) | 11% |
|
| EPS (TTM) | na | ($1.400) | na |
|
| Operating Cash Flow (TTM) (Mil) | ($88) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | na | $160 | na |
|
| Valuation | OBX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.77 | na |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | OBX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (271.6%) | (47.3%) | 1% |
|
| ROE | 69.0% | (55.0%) | 95% |
|
| Liabilities to Assets | 23.2% | 29.6% | 16% |
|
| F-Score | 1 | 2 | na |
|
Obsidian Therapeutics, Inc. did not pass any screens on 8/20/2026.
